Experts see shift toward tailored cancer therapy model Lilly awaiting details of Novo's failed trial Some drug developers target multiple biomarkers Sign up here. Globally, over 55 million people have ...
Antibodies that bind to two targets are an established way of treating the blood cancer multiple myeloma. Aiming to top those medicines, AbbVie has secured rights to an early-clinical drug that works ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback